Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 22.32% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 22.32% year-over-year, with the annual reading at $6.9 million for FY2025, 22.32% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $6.9 million at Gyre Therapeutics, up from $6.7 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $6.9 million in Q4 2025, with the low at $4.1 million in Q4 2022.
  • Average Long-Term Deferred Tax over 4 years is $5.5 million, with a median of $5.4 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax grew 15.05% in 2023, then surged 30.09% in 2025.
  • Over 4 years, Long-Term Deferred Tax stood at $4.1 million in 2022, then grew by 15.05% to $4.7 million in 2023, then grew by 19.68% to $5.6 million in 2024, then grew by 22.32% to $6.9 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $6.9 million, $6.7 million, and $6.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.